SummaryRMgm-671
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21980474 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | N.D. Gómez; K. Haldar |
Name Group/Department | Center for Rare and Neglected Diseases |
Name Institute | University of Notre Dame |
City | Notre Dame, Indiana |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-671 |
Principal name | Δmsp7 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Mutant blood stages show a minor growth defect resulting in a lower growth rate in BALB/c mice during the initial phase of infection (day 8/10). At later stages of infection (when reticulocytes are prevalent), the growth rate was similar to that of wild type parasites. In aged WISTAR rats (15 weeks) the mutant blood stages showed a reduced growth and virulence phenotype. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Figure 1
|
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1349100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1335100 | ||||||||||||||||||||||||
Gene product | merozoite surface protein 7 | ||||||||||||||||||||||||
Gene product: Alternative name | MSP7 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | No sequence information of the target sequences is provided. No information is provided for the primers used to amplify the target regions for disruption of the msp7 gene homologous recombination. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The mutant was generated using plasmid pDHΔMSP7 as previously described in RMgm-224. No sequence information of the target sequences is provided. No information is provided for the primers used to amplify the target regions for disruption of the msp7 gene homologous recombination. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |